- $12.45m
- -$302.20m
- $213.65m
Amarin Corp CEO resigns, shares fall
Brief: Amarin Corp CEO Karim Mikhail To Resign, Effective Immediately
Brief: Amarin Announces Board Departures
Brief: Amarin Highlights New Evidence Of Therapeutic Value Of EPA In Reducing Cardiovascular Events In At-Risk Patients Presented At ACC.23/WCC
Brief: Amarin Announces New Data Showing Benefit Of Vascepa In High-Risk Patients With A Recent Acute Coronary Syndrome Event
Previously Announced Cost Savings Program On-Track To Exceed $100 Million Target
Brief: Amarin Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update
Brief: Amarin Shareholders Vote To Elect Sarissa Nominees To Board, Remove Chairman
Brief: Amarin And Csl Seqirus Announce Exclusive License And Distribution Agreement To Commercialize Vazkepa In Australia And New Zealand
Brief: Amarin And Csl Seqirus Announce Exclusive License And Distribution Agreement To Commercialize Vazkepa In Australia And New Zealand
Hikma accuses Amarin of suppressing generic versions of heart pill
Brief: Amarin Corporation- Glass Lewis & Co Has Recommended That Shareholders Vote "Against" All Of Sarissa's Proposals
Brief: Sarissa Capital Urges Amarin's Shareholders To Vote Blue Proxy Card "For" Sarissa Nominees
Brief: Sarissa Capital Management LP Urges Amarin Shareholders To Vote Blue Proxy Card "For" Appointment Of Sarissa Nominees
Brief: Amarin Issues Letter To Shareholders
Brief: Amarin Corporation Mails A Letter To Shareholders Addressing Statements Made By Sarissa Capital Management
Brief: Amarin Mails Letter To Shareholders
Brief: Amarin Files Definitive Proxy Materials And Mails Letter To Shareholders
Brief: Amarin Announces Vazkepa® (Icosapent Ethyl) Approved By Medsafe In New Zealand